BioNxt Solutions Beheer

Beheer criteriumcontroles 3/4

BioNxt Solutions' CEO is Wolfgang Probst, appointed in Jul 2024, has a tenure of less than a year. directly owns 0.97% of the company’s shares, worth €189.53K. The average tenure of the management team and the board of directors is 2.4 years and 5.9 years respectively.

Belangrijke informatie

Wolfgang Probst

Algemeen directeur

CA$175.2k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	1.0%
Management gemiddelde ambtstermijn	2.4yrs
Gemiddelde ambtstermijn bestuur	5.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Wolfgang Probst's beloning veranderd ten opzichte van BioNxt Solutions's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CA$6m
Mar 31 2024	n/a	n/a	-CA$8m
Dec 31 2023	CA$175k	n/a	-CA$8m
Sep 30 2023	n/a	n/a	-CA$13m
Jun 30 2023	n/a	n/a	-CA$13m
Mar 31 2023	n/a	n/a	-CA$12m
Dec 31 2022	CA$128k	n/a	-CA$12m
Sep 30 2022	n/a	n/a	-CA$14m
Jun 30 2022	n/a	n/a	-CA$14m
Mar 31 2022	n/a	n/a	-CA$17m
Dec 31 2021	CA$216k	CA$216k	-CA$21m
Sep 30 2021	n/a	n/a	-CA$15m
Jun 30 2021	n/a	n/a	-CA$19m
Mar 31 2021	n/a	n/a	-CA$19m
Dec 31 2020	CA$184k	CA$184k	-CA$17m
Sep 30 2020	n/a	n/a	-CA$16m
Jun 30 2020	n/a	n/a	-CA$13m
Mar 31 2020	n/a	n/a	-CA$10m
Dec 31 2019	CA$178k	n/a	-CA$8m
Sep 30 2019	n/a	n/a	-CA$6m
Jun 30 2019	n/a	n/a	-CA$2m
Mar 31 2019	n/a	n/a	-CA$2m
Dec 31 2018	CA$61k	n/a	-CA$861k

Compensatie versus markt: Wolfgang's total compensation ($USD125.51K) is below average for companies of similar size in the German market ($USD488.36K).

Compensatie versus inkomsten: Wolfgang's compensation has increased whilst the company is unprofitable.

CEO

Wolfgang Probst (43 yo)

less than a year

Tenure

CA$175,164

Compensatie

Mr. Wolfgang Probst serves as Interim Chief Executive Officer of BioNxt Solutions Inc. since July 1, 2024. Mr. Probst serves as a Director at BioNxt Solutions Inc. (formerly known as XPhyto Therapeutics Co...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Wolfgang Probst	Interim CEO & Director	less than a year	CA$175.16k	0.97% € 189.5k
Patrick Meagher	CFO, Corporate Secretary & Director	3yrs	CA$78.00k	0.023% € 4.5k
Florian Sahr	Head of Project Management	2.4yrs	geen gegevens	geen gegevens

2.4yrs

Gemiddelde duur

Ervaren management: BXT's management team is considered experienced (2.4 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Wolfgang Probst	Interim CEO & Director	5.9yrs	CA$175.16k	0.97% € 189.5k
Patrick Meagher	CFO, Corporate Secretary & Director	1.2yrs	CA$78.00k	0.023% € 4.5k
Hugh A. Rogers	Director	6.9yrs	CA$188.91k	0.63% € 122.3k
Raimar Lobenberg	Independent Director	5.9yrs	CA$60.00k	4.41% € 859.6k

5.9yrs

Gemiddelde duur

43.5yo

Gemiddelde leeftijd

Ervaren bestuur: BXT's board of directors are considered experienced (5.9 years average tenure).

BioNxt Solutions Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

BioNxt Solutions Inc., Annual General Meeting, Nov 01, 2024

BioNxt Solutions Inc. Announces Change of Directors

Less than half of directors are independent

Less than half of directors are independent

XPhyto Therapeutics Corp., Annual General Meeting, Oct 12, 2022

Xphyto Therapeutics Corp. Adds Dr. Flon A. Sahr to Its European Teateam as Head of Project Management

Recent updates

BioNxt Solutions Inc. announced that it expects to receive CAD 3 million in funding

Bionxt Solutions Inc. Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent

BioNxt Solutions Inc. Receives Positive International Examination Report from the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

BioNxt Solutions Inc., Annual General Meeting, Nov 01, 2024

Second quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.024 loss in 2Q 2023)

BioNxt Solutions Inc. announced that it has received CAD 0.945 million in funding

New major risk - Share price stability

First quarter 2024 earnings released: CA$0.014 loss per share (vs CA$0.016 loss in 1Q 2023)

BioNxt Solutions Inc. Announces ODF Cladribine Update

Full year 2023 earnings released: CA$0.078 loss per share (vs CA$0.15 loss in FY 2022)

BioNxt Solutions Inc. Reports Commercialization of Odf Cladribine Product for MS Next Steps

BioNxt Solutions Inc. Reports Successful Results from ODF Cladribine PK Study

BioNxt Solutions Inc. Reports Successful Results from Odf Cladribine Toxicity Study

BioNxt Solutions Inc. announced that it has received CAD 1.168 million in funding

BioNxt Solutions Inc. announced that it expects to receive CAD 2.4 million in funding

BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing

Third quarter 2023 earnings released: CA$0.014 loss per share (vs CA$0.023 loss in 3Q 2022)

BioNxt Solutions Inc Reports on New Cladrabine Odf Product Development and Commercialization Program

BioNxt Solutions Inc. Announces Change of Directors

Second quarter 2023 earnings released: CA$0.024 loss per share (vs CA$0.017 loss in 2Q 2022)

BioNxt Solutions Inc. announced that it expects to receive CAD 3.975 million in funding

First quarter 2023 earnings released: CA$0.016 loss per share (vs CA$0.023 loss in 1Q 2022)

Bionxt Solutions Inc. Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson's Disease

Full year 2022 earnings released: CA$0.15 loss per share (vs CA$0.29 loss in FY 2021)

BioNxt Solutions Inc. Reports Update on Commercialization of Rotigotine Patch for Treatment of Parkinson's Disease

Less than half of directors are independent

BioNxt Solutions Inc. announced that it has received CAD 2.808 million in funding

BioNxt Solutions Inc. announced that it expects to receive CAD 2.6 million in funding

Third quarter 2022 earnings released: CA$0.023 loss per share (vs CA$0.036 loss in 3Q 2021)

Less than half of directors are independent

XPhyto Reports Excellent Rotigotine In-Vitro/Ex-Vivo Results for Parkinson's Disease Treatment

Xphyto Therapeutics Corp. Completes Rotigotine Transdermal Patch Optimization and Comparative Skin Absorption Study

XPhyto Therapeutics Corp. Files Patent Application for Library of Novel Psychedelic Compounds

XPhyto Therapeutics Corp. announced that it has received CAD 3.6 million in funding

Second quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.061 loss in 2Q 2021)

XPhyto Therapeutics Corp., Annual General Meeting, Oct 12, 2022

XPhyto Therapeutics Corp. announced that it expects to receive CAD 3.6 million in funding

Xphyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-Related Dental Disease

Xphyto Therapeutics Corp. Adds Dr. Flon A. Sahr to Its European Teateam as Head of Project Management

Full year 2021 earnings released: CA$0.29 loss per share (vs CA$0.29 loss in FY 2020)

Less than half of directors are independent

President recently sold €131k worth of stock

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd